GLP-1 Anti-Obesity Drugs and Addiction: What New Research Is Revealing

In recent years, drugs acting on the GLP-1 system have become central to the treatment of obesity. Originally developed for diabetes, these medications (e.g., Wegovy and Mounjaro) have demonstrated remarkable efficacy in controlling appetite and promoting weight loss.

Today, however, research is suggesting something even more intriguing: these drugs might also play a role in reducing the risk of addiction.

A recent article published in Nature highlights findings from a large study exploring the relationship between anti-obesity medications and substance-use disorders. The results open a new perspective on how metabolism, brain function and behaviour are deeply interconnected.

GLP-1 and addiction: a large study involving U.S. veterans

Researchers analysed health data from approximately 600,000 U.S. veterans, comparing individuals taking anti-obesity medications with those who were not.

The results were striking.

People treated with these drugs showed:

• a lower risk of developing substance-use disorders

• fewer complications associated with addiction, including alcohol, opioids and cocaine

• among individuals already diagnosed with substance-use disorders, about a 50% lower risk of death related to substance misuse

These are observational findings, meaning they do not yet prove a direct cause-and-effect relationship. However, they point to a highly promising area of research.

The link between appetite, the brain and the reward system

To understand these findings, we need to look at how the brain works.

Hormones such as GLP-1 do more than regulate blood sugar and satiety.

They also interact with brain circuits involved in reward and motivation, the same systems that play a central role in addictive behaviours.

These neural circuits regulate dopamine release and are activated when we experience something the brain perceives as rewarding — food, alcohol, drugs, and certain behaviours.

This is where glucose metabolism and behaviour intersect.

Obesity and addiction: more similar than we think

In recent years, research has increasingly shown that obesity and addiction share several biological mechanisms, including:

• alterations in the dopamine system

• heightened sensitivity to reward stimuli

• impaired impulse control

• compulsive behaviours

It is therefore not surprising that medications modulating compulsive eating might also influence other reward-driven behaviours.

What this could mean for the future of medicine

If these findings are confirmed by controlled clinical trials, GLP-1 medications could become part of new therapeutic strategies for conditions such as:

• alcohol-use disorder

• opioid-use disorder

• relapse prevention in addiction

This does not mean that a medication alone can solve complex conditions like addiction. These disorders always require a comprehensive approach that includes psychological support, behavioural interventions and social context.

However, this research reinforces an important concept: the human body does not function in isolated systems.

Toward a more integrated view of health

Metabolism, brain function, eating behaviour and mental health are deeply interconnected systems.

Understanding these connections is one of the most fascinating developments in modern medicine and may open new possibilities for preventing and treating many chronic diseases.

This integrated perspective is essential for developing strategies that can truly improve long-term health and quality of life.